A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension

Study Identifier
192024-081
CT.gov Identifier
NCT01830140
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Glaucoma - Other
  • Ocular Hypertension
    • Study Drug
  • Bimatoprost 0.01%
  • Bimatoprost 0.03%
    • Phase
    Phase 3
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Diagnosis of glaucoma or ocular hypertension
    Exclusion Criteria:
    * Active ocular disease other than glaucoma or ocular hypertension * Require chronic use of ocular medications other than the study medication during the study (intermittent use of artificial tear solution will be permitted)

    Protocol Summary

    This safety study will evaluate bimatoprost 0.01% and 0.03% in patients with glaucoma or ocular hypertension (OHT).

    Study Locations

    Location
    Status
    Location
    Artesia, California, United States
    Status
    Not applicable
    Location
    El Paso, Texas, United States
    Status
    Not applicable